Complete Blood Count

Actionable Insights Powered by AI

UCB Divests Mature Neurology and Allergy Portfolio in China for $680M

UCB, China, neurology, allergy, divestment, CBC Group, Mubadala, pharmaceuticals, innovation, strategic partnerships